Evidence map›Paper›PMID 31658298›Full record

ArticlePloS one2019

Off-target effects of CRISPRa on interleukin-6 expression.

Sébastien Soubeyrand, Paulina Lau, Victoria Peters, Ruth McPherson

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Epigenetic editing: from concept to clinic.Nature reviews. Drug discovery · 2026
    Review
  2. Article
  3. Review
  4. CRISPR-Cas-mediated transcriptional modulation: The therapeutic promises of CRISPRa and CRISPRi.Molecular therapy : the journal of the American Society of Gene Therapy · 2023
    Review
  5. Article
  6. Review
  7. Frontiers in genetics · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Sébastien SoubeyrandAtherogenomics Laboratory, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.ORCID 0000-0002-9317-301X
Paulina LauAtherogenomics Laboratory, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.
Victoria PetersAtherogenomics Laboratory, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.ORCID 0000-0002-3388-6632
Ruth McPhersonAtherogenomics Laboratory, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.
University of Ottawa · CA

Funding

CIHR
6 · The paper itself

Abstract

Inactive fusion variants of the CRISPR-Cas9 system are increasingly being used as standard methodology to study transcription regulation. Their ability to readily manipulate the native genomic loci is particularly advantageous. In this work, we serendipitously uncover the key cytokine IL6 as an off-target of the activating derivative of CRISPR (CRISPRa) while studying RP11-326A19.4, a novel long-non coding RNA (lncRNA). Increasing RP11-326A19.4 expression in HEK293T cells via CRISPRa-mediated activation of its promoter region induced genome-wide transcriptional changes, including upregulation of IL6, an important cytokine. IL6 was increased in response to distinct sgRNA targeting the RP11-326A19.4 promoter region, suggesting specificity. Loss of the cognate sgRNA recognition sites failed to abolish CRISPRa mediated activation of IL6 however, pointing to off-target effects. Bioinformatic approaches did not reveal predicted off-target binding sites. Off-target activation of IL6 was sustained and involved low level activation of known IL6 regulators. Increased IL6 remained sensitive to further activation by TNFα, consistent with the existence of independent mechanisms. This study provides experimental evidence that CRISPRa has discrete, unpredictable off-targeting limitations that must be considered when using this emerging technology.

Indexed as

Binding SitesClustered Regularly Interspaced Short Palindromic RepeatsGene Expression ProfilingGene Expression RegulationHEK293 CellsHeLa CellsHumansInterleukin-6Promoter Regions, GeneticRNA, Guide, CRISPR-Cas SystemsRNA, Long NoncodingTranscriptional ActivationUp-RegulationIL6 protein, humanInterleukin-6RNA, Guide, CRISPR-Cas SystemsRNA, Long Noncoding

Identifiers

PMID31658298
PMCPMC6816553
OpenAlexW2981743254

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.